Novel noninvasive biomarkers of prodromal Alzheimer disease: The role of optical coherence tomography and optical coherence tomography-angiography
Language English Country England, Great Britain Media print-electronic
Document type Journal Article
PubMed
33852770
DOI
10.1111/ene.14871
Knihovny.cz E-resources
- Keywords
- Alzheimer disease, OCT, OCT-angiography, diagnostic biomarkers, mild cognitive impairment, optical coherence tomography,
- MeSH
- Alzheimer Disease * diagnostic imaging MeSH
- Biomarkers MeSH
- Fluorescein Angiography MeSH
- Humans MeSH
- Tomography, Optical Coherence * MeSH
- Retinal Vessels diagnostic imaging MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Biomarkers MeSH
BACKGROUND AND PURPOSE: A reduction of retinal thickness and an alteration of retinal perfusion have been found in Alzheimer disease (AD). Nowadays, retinal layers and retinal perfusion can be evaluated by means of noninvasive imaging techniques, namely, optical coherence tomography (OCT) and OCT-angiography (OCT-A). Here, we have compared the retinal thickness and the perfusion index, measured by means of OCT and OCT-A, in patients with mild cognitive impairment due to AD (MCI-AD) and in age- and sex-matched cognitively healthy controls. METHODS: Twenty-four MCI-AD patients and 13 control subjects were enrolled. MCI-AD patients underwent lumbar puncture; all of them showed a cerebrospinal fluid (CSF) profile compatible with AD. OCT was used for evaluating retinal volumes and thicknesses, whereas with OCT-A we measured fractal dimension (FD), vascular perfusion density (VPD), and vessel length density (VLD) of superficial capillary plexus (SCP), intermediate capillary plexus (ICP), deep capillary plexus (DCP), and choriocapillaris. The comparisons between groups were made after adjustment for age, diabetes, and hypertension. RESULTS: A significant reduction of SCP-VLD (p = 0.012), ICP-VPD (p = 0.015), ICP-VLD (p = 0.004), DCP-VPD (p = 0.012), and DCP-VLD (p = 0.009) was found in MCI-AD patients compared to controls. Conversely, FD was higher in MCI-AD than in controls (p = 0.044). CSF Aβ42/total tau negatively correlated with FD (r = -0.51, p = 0.010). CONCLUSIONS: OCT-A might have a potential role in detecting new noninvasive biomarkers for early AD detection. Retinal VPD might identify amyloid angiopathy-related chronic injury, and FD could show early vessel recruitment as a compensative mechanism at disease onset. Further studies will be needed to confirm these findings.
Macula Onlus Foundation Di N O G Mi University Eye Clinic Genoa Italy
Section of Ophthalmology Department of Medicine and Surgery University of Perugia Perugia Italy
See more in PubMed
Albert MS, DeKosky ST, Dickson D. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 2011;7(3):270-279.
Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614-629.
Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562.
Lewczuk P, Riederer P, O'Bryant SE, et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry. 2018;19(4):244-328.
Aisen PS, Cummings J, Jack CR Jr, et al. On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimers Res Ther. 2017;9(1):60.
Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, et al. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. NeuroImage. 2011;54(Suppl 1):S204-S217.
Koronyo Y, Biggs D, Barron E, et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease. JCI Insight. 2017;2:93621.
La Morgia C, Ross-Cisneros FN, Koronyo Y, et al. Melanopsin retinal ganglion cell loss in Alzheimer disease. Ann Neurol. 2016;79:90-109.
Alexandrov PN, Pogue A, Bhattacharjee S, Lukiw WJ. Retinal amyloid pep-tides and complement factor H in transgenic models of Alzheimer's disease. NeuroReport. 2011;22:623-627.
Loffler KU, Edward DP, Tso MO. Immunoreactivity against tau, amyloid precursor protein, and beta-amyloid in the human retina. Invest Ophthalmol Vis Sci. 1995;36:24-31.
Schon C, Hoffmann NA, Ochs SM, et al. Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. PLoS ONE. 2012;7:e53547.
Tsai Y, Lu B, Ljubimov AV, et al. Ocular changes in TgF344-AD rat model of Alzheimer's disease. Invest Ophthalmol Vis Sci. 2014;55:523-534.
Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve degeneration in Alzheimer's disease. N Engl J Med. 1986;315:485-487.
Blanks JC, Schimdt SY, Torigoe Y, Porrello KV, Hilton DR, Blanks RH. Retinal pathology in Alzheimer's disease. II. Regional neuron loss and glial changes in CGL. Neurobiol Aging. 1996;17:385-395.
Doustar J, Torbati T, Black KL, Koronyo Y, Koronyo-Hamaoui M. Optical coherence tomography in Alzheimer's disease and other neurodegenerative diseases. Front Neurol. 2017;8:701.
Den Haan J, Verbraak FD, Visser PJ, Bouwman FH. Retinal thickness in Alzheimer's disease: a systematic review and meta-analysis. Alzheimers Dement. 2017;6:162-170.
Einarsdottir AB, Hardarson SH, Kristjansdottir JV, Bragason DT, Snaedal J, Stefánsson E. Retinal oximetry imaging in Alzheimer's disease. J. Alzheimer's Dis. 2015;49:79-83.
Feke GT, Hyman BT, Stern RA, Pasquale LR. Retinal blood flow in mild cognitive impairment and Alzheimer's disease. Alzheimer's Dement. 2015;1:144-151.
Gharbiya M, Trebbastoni A, Parisi F, et al. Choroidal thinning as a new finding in Alzheimer's disease: evidence from enhanced depth imaging spectral domain optical coherence tomography. J Alzheimers Dis. 2014;40:907-917.
Bayhan HA, Aslan Bayhan S, Celikbilek A, Tanik N, Gürdal C. Evaluation of the chorioretinal thickness changes in Alzheimer's disease using spectral-domain optical coherence tomography. Clin Exp Ophthalmol. 2015;43:145-151.
Girouard H, Iadecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol. 2006;100:328-335.
Bulut M, Kurtuluş F, Gözkaya O, et al. Evaluation of optical coherence tomography angiographic findings in Alzheimer's type dementia. Br J Ophthalmol. 2017;102(2):233-237. https://doi.org/10.1136/bjophthalmol-2017-310476
Jiang H, Wei Y, Shi Y, et al. Altered Macular Microvasculature in Mild Cognitive Impairment and Alzheimer Disease. J Neuroophthalmol. 2018;38:292-298.
Yoon SP, Grewal DS, Thompson AC, et al. Retinal microvascular and neurodegenerative changes in Alzheimer's disease and mild cognitive impairment compared with control participants. Ophthalmol Retina. 2019;3(6):489-499.
den Haan J, van de Kreeke JA, Konijnenberg E, et al. Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease. Alzheimer's Dement (Amsterdam, Netherlands). 2019;11:463-471.
Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73:1914-1922.
Phansalkar N, More S, Sabale A, et al. Adaptive local thresholding for detection of nuclei in diversity stained cytology images. Proc International ConfCommunSignalProcess. 2011;218-220.
Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci. 2004;5:347-360.
Scheltens P, Blennow K, Breteler MM, et al. Alzheimer's disease. Lancet. 2016;388:505-517.
Lupidi M, Coscas F, Cagini C, et al. Automated quantitative analysis of retinal microvasculature in normal eyes on optical coherence tomography angiography. Am J Ophthalmol. 2016;169:9-23.
Coscas G, Lupidi M, Coscas F. Image analysis of optical coherence tomography angiography. DevOphthalmol. 2016;56:30-36.
Kraker JA, Omoba BS, Cava JA, et al. Assessing the influence of OCT-A device and scan size on retinal vascular metrics. Transl Vis Sci Technol. 2020;9(11):7.
Lavia C, Bonnin S, Maule M, Erginay A, Tadayoni R, Gaudric A. Vessel density of superficial, intermediate, and deep capillary plexuses using optical coherence tomography angiography. Retina. 2019;39(2):247-258.
Lei J, Durbin MK, Shi Y, et al. Repeatability and reproducibility of superficial macular retinal vessel density measurements using optical coherence tomography angiography en face images. JAMA Ophthalmol. 2017;135(10):1092-1098. https://doi.org/10.1001/jamaophthalmol.2017.3431
Durbin MK, An L, Shemonski ND, et al. Quantification of retinal microvascular density in optical coherence tomographic angiography images in diabetic retinopathy. JAMA Ophthalmol. 2017;135(4):370-376. https://doi.org/10.1001/jamaophthalmol.2017.0080
Wu J, Zhang X, Azhati G, Li T, Xu G, Liu F. Retinal microvascular attenuation in mental cognitive impairment and Alzheimer's disease by optical coherence tomography angiography. Acta Ophthalmol. 2020;98(6):e781-e787.
Palochak CMA, Lee HE, Song J, et al. Retinal Blood Velocity and Flow in Early Diabetes and Diabetic Retinopathy Using Adaptive Optics Scanning Laser Ophthalmoscopy.
Nadal J, Deverdun J, de Champfleur NM, et al. Retinal vascular fractal dimension and cerebral blood flow, a pilot study. ActaOphthalmol. 2020;98(1):e63-e71.
Dumitrascu OM, Lyden PD, Torbati T, et al. Sectoral segmentation of retinal amyloid imaging in subjects with cognitive decline. Alzheimers Dement (Amst). 2020;12(1):e12109.
